|
1
|
Spillane AJ, Fisher C and Thomas JM:
Myxoid liposarcoma-the frequency and the natural history of
nonpulmonary soft tissue metastases. Ann Surg Oncol. 6:389–394.
1999.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Manji GA and Schwartz GK: Managing
liposarcomas: Cutting through the fat. J Oncol Pract. 12:221–227.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zheng K, Yu XC, Xu M and Yang Y: Surgical
outcomes and prognostic factors of myxoid liposarcoma in
extremities: A retrospective study. Orthop Surg. 11:1020–1028.
2019.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Shinoda Y, Kobayashi E, Kobayashi H, Mori
T, Asano N, Nakayama R, Morioka H, Iwata S, Yonemoto T, Ishii T, et
al: Prognostic factors of metastatic myxoid liposarcoma. BMC
Cancer. 20(883)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Crozat A, Aman P, Mandahl N and Ron D:
Fusion of CHOP to a novel RNA-binding protein in human myxoid
liposarcoma. Nature. 363:640–644. 1993.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Rabbitts TH, Forster A, Larson R and
Nathan P: Fusion of the dominant negative transcription regulator
CHOP with a novel gene FUS by translocation t(12;16) in malignant
liposarcoma. Nat Genet. 4:175–180. 1993.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Panagopoulos I, Höglund M, Mertens F,
Mandahl N, Mitelman F and Aman P: Fusion of the EWS and CHOP genes
in myxoid liposarcoma. Oncogene. 12:489–494. 1996.PubMed/NCBI
|
|
8
|
Sánchez-García I and Rabbitts TH:
Transcriptional activation by TAL1 and FUS-CHOP proteins expressed
in acute malignancies as a result of chromosomal abnormalities.
Proc Natl Acad Sci USA. 91:7869–7873. 1994.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kuroda M, Wang X, Sok J, Yin Y, Chung P,
Giannotti JW, Jacobs KA, Fitz LJ, Murtha-Riel P, Turner KJ and Ron
D: Induction of a secreted protein by the myxoid liposarcoma
oncogene. Proc Natl Acad Sci USA. 96:5025–5030. 1999.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Thelin-Järnum S, Lassen C, Panagopoulos I,
Mandahl N and Aman P: Identification of genes differentially
expressed in TLS-CHOP carrying myxoid liposarcomas. Int J Cancer.
83:30–33. 1999.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Riggi N, Cironi L, Provero P, Suvà ML,
Stehle JC, Baumer K, Guillou L and Stamenkovic I: Expression of the
FUS-CHOP fusion protein in primary mesenchymal progenitor cells
gives rise to a model of myxoid liposarcoma. Cancer Res.
66:7016–7023. 2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pérez-Mancera PA, Bermejo-Rodríguez C,
Sánchez-Martín M, Abollo-Jiménez F, Pintado B and Sánchez-García I:
FUS-DDIT3 prevents the development of adipocytic precursors in
liposarcoma by repressing PPARgamma and C/EBPalpha and activating
eIF4E. PLoS One. 3(e2569)2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Fisher PB, Gopalkrishnan RV, Chada S,
Ramesh R, Grimm EA, Rosenfeld MR, Curiel DT and Dent P:
mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine
gene: from the laboratory into the clinic. Cancer Biol Ther. 2 (4
Suppl 1):S23–S37. 2003.PubMed/NCBI
|
|
14
|
Jiang H, Lin JJ, Su ZZ, Goldstein NI and
Fisher PB: Subtraction hybridization identifies a novel melanoma
differentiation associated gene, mda-7, modulated during human
melanoma differentiation, growth and progression. Oncogene.
11:2477–2486. 1995.PubMed/NCBI
|
|
15
|
Huang EY, Madireddi MT, Gopalkrishnan RV,
Leszczyniecka M, Su Z, Lebedeva IV, Kang D, Jiang H, Lin JJ,
Alexandre D, et al: Genomic structure, chromosomal localization and
expression profile of a novel melanoma differentiation associated
(mda-7) gene with cancer specific growth suppressing and apoptosis
inducing properties. Oncogene. 20:7051–7063. 2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ellerhorst JA, Prieto VG, Ekmekcioglu S,
Broemeling L, Yekell S, Chada S and Grimm EA: Loss of MDA-7
expression with progression of melanoma. J Clin Oncol.
20:1069–1074. 2002.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dash R, Bhutia SK, Azab B, Su ZZ, Quinn
BA, Kegelmen TP, Das SK, Kim K, Lee SG, Park MA, et al:
mda-7/IL-24: A unique member of the IL-10 gene family promoting
cancer-targeted toxicity. Cytokine Growth Factor Rev. 21:381–391.
2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rahmani M, Mayo M, Dash R, Sokhi UK,
Dmitriev IP, Sarkar D, Dent P, Curiel DT, Fisher PB and Grant S:
Melanoma differentiation associated gene-7/interleukin-24 potently
induces apoptosis in human myeloid leukemia cells through a process
regulated by endoplasmic reticulum stress. Mol Pharmacol.
78:1096–1104. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Oikawa K, Tanaka M, Itoh S, Takanashi M,
Ozaki T, Muragaki Y and Kuroda M: A novel oncogenic pathway by
TLS-CHOP involving repression of MDA-7/IL-24 expression. Br J
Cancer. 106:1976–1979. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gupta P, Su ZZ, Lebedeva IV, Sarkar D,
Sauane M, Emdad L, Bachelor MA, Grant S, Curiel DT, Dent P and
Fisher PB: mda-7/IL-24: Multifunctional cancer-specific
apoptosis-inducing cytokine. Pharmacol Ther. 111:596–628.
2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Oikawa K, Mizusaki A, Takanashi M, Ozaki
T, Sato F, Kuroda M and Muragaki Y: PRG4 expression in myxoid
liposarcoma maintains tumor cell growth through suppression of an
antitumor cytokine IL-24. Biochem Biophys Res Commun. 485:209–214.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gopalan B, Shanker M, Scott A, Branch CD,
Chada S and Ramesh R: MDA-7/IL-24, a novel tumor
suppressor/cytokine is ubiquitinated and regulated by the
ubiquitin-proteasome system, and inhibition of MDA-7/IL-24
degradation enhances the antitumor activity. Cancer Gene Ther.
15:1–8. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Li S, Wei X, He J, Tian X, Yuan S and Sun
L: Plasminogen activator inhibitor-1 in cancer research. Biomed
Pharmacother. 105:83–94. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Borjigin N, Ohno S, Wu W, Tanaka M, Suzuki
R, Fujita K, Takanashi M, Oikawa K, Goto T, Motoi T, et al:
TLS-CHOP represses miR-486 expression, inducing upregulation of a
metastasis regulator PAI-1 in human myxoid liposarcoma. Biochem
Biophys Res Commun. 427:355–360. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Oikawa K, Ohbayashi T, Mimura J,
Fujii-Kuriyama Y, Teshima S, Rokutan K, Mukai K and Kuroda M:
Dioxin stimulates synthesis and secretion of IgE-dependent
histamine-releasing factor. Biochem Biophys Res Commun.
290:984–987. 2002.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Oikawa K, Ohbayashi T, Kiyono T, Nishi H,
Isaka K, Umezawa A, Kuroda M and Mukai K: Expression of a novel
human gene, human wings apart-like (hWAPL), is associated with
cervical carcinogenesis and tumor progression. Cancer Res.
64:3545–3549. 2004.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Placencio VR, Ichimura A, Miyata T and
DeClerck YA: Small molecule inhibitors of plasminogen activator
inhibitor-1 elicit anti-tumorigenic and anti-angiogenic activity.
PLoS One. 10(e0133786)2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mashiko S, Kitatani K, Toyoshima M,
Ichimura A, Dan T, Usui T, Ishibashi M, Shigeta S, Nagase S, Miyata
T and Yaegashi N: Inhibition of plasminogen activator inhibitor-1
is a potential therapeutic strategy in ovarian cancer. Cancer Biol
Ther. 16:253–260. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Nakatsuka E, Sawada K, Nakamura K,
Yoshimura A, Kinose Y, Kodama M, Hashimoto K, Mabuchi S, Makino H,
Morii E, et al: Plasminogen activator inhibitor-1 is an independent
prognostic factor of ovarian cancer and IMD-4482, a novel
plasminogen activator inhibitor-1 inhibitor, inhibits ovarian
cancer peritoneal dissemination. Oncotarget. 8:89887–89902.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tsuge M, Osaki M, Sasaki R, Hirahata M and
Okada F: SK-216, a novel inhibitor of plasminogen activator
inhibitor-1, suppresses lung metastasis of human osteosarcoma. Int
J Mol Sci. 19(736)2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Xi X, Liu N, Wang Q, Chu Y, Yin Z, Ding Y
and Lu Y: ACT001, a novel PAI-1 inhibitor, exerts synergistic
effects in combination with cisplatin by inhibiting PI3K/AKT
pathway in glioma. Cell Death Dis. 10(757)2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tseng YJ, Lee CH, Chen WY, Yang JL and
Tzeng HT: Inhibition of PAI-1 blocks PD-L1 endocytosis and improves
the response of melanoma cells to immune checkpoint blockade. J
Invest Dermatol. 141:2690–2698.e6. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Modi J, Roy A, Pradhan AK, Kumar A,
Talukdar S, Bhoopathi P, Maji S, Mannangatti P, Sanchez De La Rosa
D, Li J, et al: Insights into the mechanisms of action of
MDA-7/IL-24: A ubiquitous cancer-suppressing protein. Int J Mol
Sci. 23(72)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Emdad L, Bhoopathi P, Talukdar S, Pradhan
AK, Sarkar D, Wang XY, Das SK and Fisher PB: Recent insights into
apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a
multidimensional anti-cancer therapeutic. Semin Cancer Biol.
66:140–154. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Madireddi MT, Dent P and Fisher PB: AP-1
and C/EBP transcription factors contribute to mda-7 gene promoter
activity during human melanoma differentiation. J Cell Physiol.
185:36–46. 2000.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Pan L, Pan H, Jiang H, Du J, Wang X, Huang
B and Lu J: HDAC4 inhibits the transcriptional activation of
mda-7/IL-24 induced by Sp1. Cell Mol Immunol. 7:221–226.
2010.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Boncela J, Przygodzka P, Papiewska-Pajak
I, Wyroba E, Osinska M and Cierniewski CS: Plasminogen activator
inhibitor type 1 interacts with alpha3 subunit of proteasome and
modulates its activity. J Biol Chem. 286:6820–6831. 2011.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Sillen M, Miyata T, Vaughan DE, Strelkov
SV and Declerck PJ: Structural insight into the two-step mechanism
of PAI-1 inhibition by small molecule TM5484. Int J Mol Sci.
22(1482)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Balsara RD and Ploplis VA: Plasminogen
activator inhibitor-1: The double-edged sword in apoptosis. Thromb
Haemost. 100:1029–1036. 2008.PubMed/NCBI
|
|
40
|
Kubala MH and DeClerck YA: The plasminogen
activator inhibitor-1 paradox in cancer: A mechanistic
understanding. Cancer Metastasis Rev. 38:483–492. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Fang H, Placencio VR and DeClerck YA:
Protumorigenic activity of plasminogen activator inhibitor-1
through an antiapoptotic function. J Natl Cancer Inst.
104:1470–1484. 2012.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Domoto H, Hosaka T, Oikawa K, Ohbayashi T,
Ishida T, Izumi M, Iwaya K, Toguchida J, Kuroda M and Mukai K:
TLS-CHOP target gene DOL54 expression in liposarcomas and malignant
fibrous histiocytomas. Pathol Int. 52:497–500. 2002.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Panagopoulos I, Mertens F, Isaksson M and
Mandahl N: Expression of DOL54 is not restricted to myxoid
liposarcomas with the FUS-DDIT3 chimera but is found in various
sarcomas. Oncol Rep. 12:107–110. 2004.PubMed/NCBI
|
